To evaluate the efficacy and safety of subcutaneous anifrolumab for adult patients with systemic lupus erythematosus.
Key Findings:
Anifrolumab significantly reduced disease activity compared to placebo.
29% of patients achieved remission based on Definitions of Remission in Systemic Lupus Erythematosus criteria.
40.1% reached low disease activity status as measured by the Low-Level Disease Activity Score.
Improvements in clinical outcomes while tapering corticosteroid doses.
Interpretation:
Anifrolumab provides a new self-administered treatment option for systemic lupus erythematosus, potentially reducing reliance on intravenous therapy and corticosteroids.
Limitations:
The study population may not fully represent all demographics affected by systemic lupus erythematosus.
Long-term safety and efficacy data are still needed.
Conclusion:
The approval of subcutaneous anifrolumab offers a significant advancement in the management of systemic lupus erythematosus, allowing for self-administration and improved patient outcomes.
A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.
